CERDELGA (ELIGLUSTAT) | Pharmaceutical Consulting Companies

What is CERDELGA and how could it be utilized? 

CERDELGA is a professionally prescribed medication utilized for the drawn-out treatment of Gaucher sickness type 1 (GD1) in grown-ups. 

CERDELGA isn't utilized in specific individuals with Gaucher illness type 1. Your primary care physician will play out a test to ensure that CERDELGA is ideal for you.  pharmaceutical consulting companies.

It isn't known whether CERDELGA is protected and successful in youngsters. 

What are the conceivable results of CERDELGA? 

See "What is the main data I should think about CERDELGA?" 

CERDELGA, utilized with certain different drugs, may cause changes in the electrical movement of your heart (ECG changes) and sporadic heartbeat (arrhythmias). Tell your PCP on the off chance that you have new side effects like palpitations, swooning, or unsteadiness. 

The most widely recognized symptoms of CERDELGA include sleepiness, migraine, queasiness, runs, and agony in the arms, legs, back, or stomach (midsection). 

Tell your PCP in the event that you have any result that pesters you or that doesn't disappear. These are not every one of the conceivable symptoms of CERDELGA. 

Call your primary care physician for clinical guidance about results. You may report results to FDA at 1-800-FDA-1088. 

How could I store CERDELGA? 

Store CERDELGA at room temperature between 68°F to 77 °F (20°C to 25 °C). 

Keep CERDELGA and all meds far from kids. 

General data about the protected and powerful utilization of CERDELGA. 

Drugs are in some cases endorsed for purposes other than those recorded in a Medication Guide. Try not to utilize CERDELGA for a condition for which it was not endorsed. Try not to offer CERDELGA to others, regardless of whether they have similar indications you have. It might hurt them. 

On the off chance that you might want more data, talk with your primary care physician. You can ask your PCP or drug specialist for data about CERDELGA that is composed of wellbeing experts. 

Depiction 

CERDELGA (eliglustat) cases contain eliglustat tartrate, which is a little particle inhibitor of glucosylceramide synthase that takes after the ceramide substrate for the catalyst, with the synthetic name N-((1R,2R)- 1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)- 1-hydroxy-3-(pyrrolidine-1-yl)propane-2-yl)cyanamide (2R,3R)- 2,3-dihydroxysuccinate. Its sub-atomic weight is 479.59, and the exact equation is C23H36N2O4+½(C4H6O6) with the accompanying substance structure: 

CERDELGA® (eliglustat) Structural Formula - Illustration 

Each case of CERDELGA for oral use contains 84 mg of eliglustat (comparable to 100 mg of eliglustat tartrate). The latent fixings are candurin silver fine, FD&C blue 2, gelatin, glyceryl behenate, hypromellose, lactose monohydrate, microcrystalline cellulose, and yellow iron oxide.